Introduction
============

Oral cancer is the most frequently observed cancer of the head and neck region worldwide, with \~363,000 new cases reported annually and a mortality rate of \~50% ([@b1-ol-0-0-5497],[@b2-ol-0-0-5497]). The tongue is a vital organ that serves an essential role in speech and swallowing. Tongue cancer, a form of oral cancer, has become one of the greatest challenges in the head and neck cancer field ([@b3-ol-0-0-5497]). It has been reported that tongue cancer comprises between 22 and 49% of all oral cancer ([@b4-ol-0-0-5497]). Tongue cancer begins as a small lump and may spread throughout the tongue and to the gums ([@b5-ol-0-0-5497]). It has been estimated that 6--7% of tongue cancer occurs in patients \<40 years old ([@b6-ol-0-0-5497]).

Tongue cancer may be caused by numerous factors, including old age, geographical location, family history, nutritional deficiencies, infectious agents, and chronic alcohol and tobacco use ([@b7-ol-0-0-5497]), however, the exact cause is unknown. A previous study demonstrated that cyclin D1 was overexpressed in patients with anterior tongue cancer with no history of tobacco and alcohol use, and postulated that it may contribute to the development of this cancer. A total of 18 DEGs were identified in this study ([@b8-ol-0-0-5497]). Another study reported that tumor protein p53, BCL2 associated X apoptosis regulator and BCL2 apoptosis regulator were associated with squamous cell cancer of the tongue ([@b9-ol-0-0-5497]). Therefore, although previous studies have identified a number of genes and proteins associated with tongue cancer, the exact pathogenesis of the disease remains unknown.

The present study investigated gene expression profiles to identify differentially-expressed genes (DEGs) between tongue cancer from patients with a history of tobacco and/or alcohol use (habit group) and tongue cancer from non-habit-associated patients (non-habit group). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were then performed to analyze the DEGs. Several key genes associated with habit-associated tongue cancer were identified through protein-protein interaction (PPI) network and functional module analysis. These results provide insight into the molecular mechanisms underlying habit-associated tongue cancer. In addition, the key DEGs identified are potential therapeutic targets for the treatment of tongue cancer in patients with a history of tobacco and/or alcohol use.

Materials and methods
=====================

### Microarray data

The gene expression profile of microarray dataset GSE42023 was obtained from the Gene Expression Omnibus (GEO) database ([www.ncbi.nlm.nih.gov/geo](www.ncbi.nlm.nih.gov/geo)). This dataset was originally produced using the HumanHT-8 v3.0 Gene Expression BeadChip Array (Illumina, Inc., San Diego, CA, USA) ([@b8-ol-0-0-5497]). Gene expression data from 22 human anterior tongue cancer tissue samples were analyzed in this study, including 10 habit-associated samples, which were obtained from patients who had a long history (\>10 years) of tobacco and/or alcohol use, in addition to 12 non-habit associated samples, which were taken from patients who had no prior history of tobacco and/or alcohol use. Details of the patients included in this dataset are listed in [Table I](#tI-ol-0-0-5497){ref-type="table"}. The gene expression data of all samples was pre-processed through background correction, quantile normalization, probe summarization and probe ID to gene symbol using the Robust Multi-array Average algorithm ([@b10-ol-0-0-5497]) in the affy software package (version 1.8.31) of Bioconductor (<http://www.bioconductor.org/packages/release/bioc/html>).

### DEG analysis

The Linear Models for Microarray Data software package (version 3.16.8) ([@b11-ol-0-0-5497]) from Bioconductor (version 2.12; <http://www.bioconductor.org/packages/release/bioc/html/limma.html>) was used to identify DEGs between the habit and non-habit groups. DEGs with a cutoff criteria of P\<0.05 and \|log~2~ fold-change\| value ≥1 were used for screening.

### GO and KEGG pathway enrichment analysis

The Database for Annotation, Visualization and Integrated Discovery (DAVID; version 6.7; <https://david.ncifcrf.gov>) ([@b12-ol-0-0-5497]) was used to identify the GO ([@b13-ol-0-0-5497]) biological process associated with the DEGs identified. KEGG ([@b14-ol-0-0-5497]) pathway enrichment analysis was subsequently used to identify the primary signaling pathways the DEGs functioned in. P\<0.05 calculated by Fisher\'s exact test was used as the cutoff criterion for statistically significant GO and KEGG enrichment analysis.

### Screening for transcription factors (TFs) and tumor-associated genes (TAGs)

TFs and TAGs were identified from the DEGs using the Encyclopedia of DNA Elements database (<https://www.encodeproject.org>) ([@b15-ol-0-0-5497]) and the TAG database (<http://www.binfo.ncku.edu.tw/TAG>) ([@b16-ol-0-0-5497]), respectively.

### PPI network construction

The Search Tool for the Retrieval of Interacting Genes (STRING; version 9.05; <http://string-db.org>) database, which provides experimental and predicted PPI information ([@b17-ol-0-0-5497]), was used to analyze the PPI network for the DEGs. A confidence score \>0.4 was chosen as the threshold for a significant interaction. Finally, the PPI network for the remaining DEGs was visualized using Cytoscape software (version 3.0.0; [www.cytoscape.org](www.cytoscape.org)) ([@b18-ol-0-0-5497]).

### Screening and analysis of the functional module

The BioNet Package (version 1.8.0; <http://bionet.bioapps.biozentrum.uni-wuerzburg.de>) provides a set of statistics for the analysis of gene expression data and biological networks ([@b19-ol-0-0-5497]). The functional module for DEGs was obtained based on BioNet analysis of the PPI network. A false discovery rate \<0.005 was used as the cutoff criterion for functional module screening. GO and KEGG enrichment analysis of functional modules was performed using DAVID, with a statistically significant cutoff criterion of P\<0.05.

Results
=======

### Identification of DEGs

The microarray dataset GSE42023 was obtained from the GEO database in order to identify the DEGs between the habit and non-habits groups. In total, 642 DEGs were identified in the habit group compared with the non-habit group, including 200 upregulated and 442 downregulated DEGs.

### GO and KEGG functional enrichment analysis

GO enrichment analysis demonstrated that the upregulated DEGs were enriched in 29 biological processes, including regulation of apoptosis (P=0.00531), skeletal muscle tissue development (P=0.00773) and positive regulation of nuclear factor-kB transcription factor activity (P=0.00485) ([Table II](#tII-ol-0-0-5497){ref-type="table"}). The downregulated DEGs were identified to be enriched in 39 biological processes, including fat cell differentiation (P=0.00074), response to ultraviolet light (P=0.00118) and embryonic pattern specification (P=0.01686) ([Table II](#tII-ol-0-0-5497){ref-type="table"}).

KEGG enrichment analysis identified that the upregulated DEGs were significantly enriched in 9 signaling pathways, including that of calcium (P=0.01949), long-term potentiation (P=0.00326) and the spliceosome (P=0.02543) ([Table III](#tIII-ol-0-0-5497){ref-type="table"}). The downregulated DEGs were significantly enriched in 5 signaling pathways, such as the adipocytokine signaling pathway (P=0.00374), the B cell receptor signaling pathway (P=0.00607) and the non-small cell lung cancer-associated signaling pathway (P=0.03098) ([Table III](#tIII-ol-0-0-5497){ref-type="table"}).

### Screening for TFs and TAGs

A total of 31 DEGs were identified as TFs, including 10 upregulated DEGs \[e.g., E1A binding protein p300 (*EP300*), *RARG* and *HOXB13*\] and 21 downregulated DEGs (e.g. *CTBP1*, *GTF2A1* and *RORB*) ([Table IV](#tIV-ol-0-0-5497){ref-type="table"}). Furthermore, 41 DEGs were identified as TAGs, including 13 upregulated DEGs \[e.g., erb-b2 receptor tyrosine kinase 2 (*ERBB2*), *FGF8* and *MLLT11*\] and 28 downregulated DEGs \[e.g., AKT serine/threonine kinase 1 (*AKT1*), *MLF1* and *FGF20*\] ([Table IV](#tIV-ol-0-0-5497){ref-type="table"}).

### Construction of the PPI network

The DEG PPI network was constructed using STRING. The resulting PPI network contained 330 nodes and 462 PPIs ([Fig. 1](#f1-ol-0-0-5497){ref-type="fig"}). The top 10% of nodes were classified as having a high degree of connectivity in the PPI network, these included *AKT1*, *EP300*, *CALM2* and *PIK3R1* ([Table V](#tV-ol-0-0-5497){ref-type="table"}). *AKT1* was identified to interact with *ERBB2*, epiregulin (*EREG*) and *EP300* ([Fig. 1](#f1-ol-0-0-5497){ref-type="fig"}).

### Construction and analysis of the functional module

Based on the PPI network created, a functional module was constructed by BioNet. The functional module contained 33 nodes and 35 PPIs ([Fig. 2](#f2-ol-0-0-5497){ref-type="fig"}). The connectivity degree of *AKT1*, *CALM2*, *GNB2L1* and *ERBB2* was \>4 in the functional module (data not shown). DEGs in the functional module were enriched in 18 biological processes defined by GO, including protein autophosphorylation (P=0.0000425), female pregnancy (P=0.00034), positive regulation of GTPase activity (P=0.00037) and cytokine-mediated signaling (P=0.00586) ([Table VI](#tVI-ol-0-0-5497){ref-type="table"}). KEGG enrichment analysis demonstrated that the DEGs in the functional module were enriched in 16 signaling pathways, such as the ErbB signaling pathway (P=0.00126; e.g., *EREG*, *ERBB2* and *AKT1*), the focal adhesion pathway (P=0.01310; e.g., *RASGRF1*, *ERBB2* and *AKT1*) and cancer-associated pathways (P=0.04696; e.g., *DAPK3*, *ERBB2* and *ATK1*) ([Table VII](#tVII-ol-0-0-5497){ref-type="table"}).

Discussion
==========

Tongue cancer has been associated with a number of factors, including old age, geographical location and family history ([@b7-ol-0-0-5497]). In addition, tongue cancer is associated with certain habits, such as chewing betel nuts, smoking and alcohol abuse ([@b3-ol-0-0-5497]). Although knowledge of tongue cancer has progressed, the complex pathogenesis of the cancer remains unclear. Therefore, there is a requirement to investigate the molecular mechanisms underlying the pathogenesis of tongue cancer and to screen for novel markers of the disease. In the present study, the gene expression profiles of habit- and non-habit-associated tongue cancer samples were analyzed using bioinformatics methods. A total of 642 DEGs were identified between the habit and non-habit groups. Through analysis of the biological functions and pathways of the DEGs, a set of genes and signaling pathways was identified to be associated with habit-associated tongue cancer.

In the PPI network constructed, *EP300* and *AKT1* exhibited a high degree of connectivity. EP300, also known as p300, is a global transcriptional coactivator that regulates the activity of numerous DNA-binding transcription factors that are associated with a wide array of cellular activities, such as cell growth and differentiation ([@b20-ol-0-0-5497],[@b21-ol-0-0-5497]), which are increased in uncontrolled malignant tumors ([@b22-ol-0-0-5497]). EP300 has been found to be involved in DNA repair synthesis through its interaction with proliferating cell nuclear antigen, which is essential for DNA replication ([@b23-ol-0-0-5497],[@b24-ol-0-0-5497]). To the best of our knowledge, there is no evidence that *EP300* is associated with habit-associated tongue cancer currently. However, EP300 has been found to promote cancer progression in the prostate ([@b25-ol-0-0-5497]) and colon ([@b26-ol-0-0-5497]). Thus, EP300 may serve a role in the development of habit-associated tongue cancer, likely through regulating cell growth.

AKT1 belongs to the Akt/protein kinase B subfamily of serine/threonine kinases, which is frequently hyperactivated in human cancer ([@b27-ol-0-0-5497]). The AKT family (AKT1-3) has been found to integrate extracellular signals in several cellular processes, including growth, proliferation, differentiation, migration and survival ([@b28-ol-0-0-5497]). Numerous studies have demonstrated that the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin pathway serves an essential role in apoptosis and is frequently activated in numerous types of human cancer, such as head and neck squamous cell carcinoma ([@b29-ol-0-0-5497],[@b30-ol-0-0-5497]), prostate cancer ([@b31-ol-0-0-5497]), breast cancer ([@b32-ol-0-0-5497]) and colorectal cancer ([@b33-ol-0-0-5497]). Cancer cells have a higher proliferation rate compared with wild-type cells and frequently lose the ability to undergo apoptosis ([@b18-ol-0-0-5497]). A previous study reported that activated AKT regulates its downstream targets to increase proliferation and decrease apoptosis in cells ([@b34-ol-0-0-5497]). AKT activation has been described as an early cellular response to carcinogen exposure and may be a key step in environmental carcinogenesis ([@b35-ol-0-0-5497]). In the current study, *AKT1* was identified to be significantly functionally enriched in cancer-associated signaling pathways. The overexpression of AKT has been detected in a variety of cancer types, including tongue cancer ([@b36-ol-0-0-5497]), head and neck squamous cell carcinoma ([@b37-ol-0-0-5497]), ovarian cancer ([@b38-ol-0-0-5497]) and prostate cancer ([@b39-ol-0-0-5497]). There is no evidence, to the best of our knowledge, that *AKT1* is associated with habit-associated tongue cancer at present. However, AKT1 may be associated with the development of habit-associated tongue cancer via the regulation of cell proliferation and differentiation.

In the current study, *AKT1*, *ERBB2* and *EREG* were demonstrated to be significantly functionally enriched in the ErbB signaling pathway. The ErbB signaling pathway regulates cell migration and invasion in normal and tumor mammary epithelial cells ([@b40-ol-0-0-5497]). The ErbB family, which consists of four members \[epidermal growth factor receptor (EGFR), ERBB2, ERBB3 and ERBB4\], plays an important role in cell proliferation and survival in numerous epithelial malignancies ([@b41-ol-0-0-5497]). *ERBB2* was predicted to be a TAG in the current study. The overexpression of ERBB2 particularly occurs with a high frequency in breast cancer ([@b42-ol-0-0-5497]). In addition, Silva *et al* ([@b43-ol-0-0-5497]) reported that ERBB2 expression is associated with the 10-year survival of patients with tongue cancer ([@b43-ol-0-0-5497]), indicating that ERBB2 serves an important role in tongue cancer development and progression. However, to the best of our knowledge, there have been no reports of an association between ERBB2 and habit-associated tongue cancer thus far. EGFR regulates cell motility, invasion and proliferation ([@b44-ol-0-0-5497]). *EGFR* mutations have been identified to activate anti-apoptotic signaling pathways, such as PI3K/AKT/mTOR and mitogen-activated protein kinase ([@b45-ol-0-0-5497]). EREG, as a ligand of EGFR, stimulates the EGFR signaling pathway, which promotes the metastasis of breast cancer cells ([@b46-ol-0-0-5497]). The results of the current study identified that AKT1 interacts with EREG in the PPI network. In addition, AKT1 and ERBB2 were classified as oncogenes using the TAG database. These results indicate that AKT1, ERBB2 and EREG are associated with the tumorigenesis of habit-associated tongue cancer and are potential therapeutic targets for the treatment of this cancer.

The grade of the tumor samples in the microarray dataset used in the present study was different between the habit and non-habit groups ([Table I](#tI-ol-0-0-5497){ref-type="table"}). The grade of the tumor may impact gene expression, so this should be taken into consideration when interpreting the results. In future, a more accurate comparison could be made if tumor samples of different grades were divided into subgroups. In addition, the results of the present study will be validated experimentally.

In conclusion, the present study identified key DEGs in habit-associated tongue cancer. These DEGs, such as *AKT1*, *EP300*, *ERBB2* and *EREG*, may serve important roles in the tumorigenesis of habit-associated tongue cancer and could be used as therapeutic targets for the treatment of this cancer. However, further experiments are required to verify the results of the current study and increase our understanding of the pathogenesis of habit-associated tongue cancer.
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###### 

Details of patients with habit and non-habit associated tongue cancer in the GSE42023 microarray dataset.

  Category                                     Sample number   Gender (M/F)   Age (years)   Tumor grade
  -------------------------------------------- --------------- -------------- ------------- ---------------------------
  Habit-associated tongue cancer samples         1             M              37            Moderately-differentiated
                                                 2             M              45            Moderately-differentiated
                                                 3             M              52            Moderately-differentiated
                                                 4             M              42            Moderately-differentiated
                                                 5             M              45            Well-differentiated
                                                 6             M              42            Well-differentiated
                                                 7             M              41            Well-differentiated
                                                 8             M              52            Well-differentiated
                                                 9             M              67            Well-differentiated
                                               10              F              48            Moderately-differentiated
  Non-habit-associated tongue cancer samples     1             M              30            Moderately-differentiated
                                                 2             M              36            Moderately-differentiated
                                                 3             M              37            Well-differentiated
                                                 4             F              50            Well-differentiated
                                                 5             F              80            Well-differentiated
                                                 6             F              40            Moderately-differentiated
                                                 7             F              25            Well-differentiated
                                                 8             F              46            Moderately-differentiated
                                                 9             F              50            Moderately-differentiated
                                                 10            F              63            Well-differentiated
                                               11              F              70            Well-differentiated
                                               12              F              56            Well-differentiated

Microarray dataset GSE42023 was obtained from the Gene Expression Omnibus database and was originally produced by Sebastian *et al* ([@b8-ol-0-0-5497]). M, male; F, female.

###### 

Top 10 enriched GO functions for upregulated and downregulated DEGs.

  Type of DEG     GO no.         GO function                                                             No. of DEGs enriched   P-value^[a](#tfn2-ol-0-0-5497){ref-type="table-fn"}^   Genes
  --------------- -------------- ----------------------------------------------------------------------- ---------------------- ------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Upregulated     GO:0042981     Regulation of apoptotic process                                         21                     0.00531                                                *TEX11*, *MST4*, *FGF8*, *FHL2*, *RARG*, *DNAJC5*, *APAF1*, *PRKCZ*, *TNFRSF10B*, *IFI27*, *INSL3*, *CTH*, *PSMB10*, *MLLT11*, *KDM2B*, *DAPK3*, *SCG2*, *MTDH*, *CLU*, *SHQ1*, *GRM4*
                  GO:0007519     Skeletal muscle tissue development                                        7                    0.00773                                                *RCAN1*, *ERBB2*, *TCF21*, *CHRNA1*, *ADAM12*, *MYEF2*, *EP300*
                  GO:0051092     Positive regulation of NF-kB transcription factor activity                5                    0.00485                                                *TLR9*, *PRKCZ*, *CTH*, *MTDH*, *CLU*
                  GO:0021532     Neural tube patterning                                                    3                    0.00499                                                *FGF8*, *FOXA2*, *KDM2B*
                  GO:0060425     Lung morphogenesis                                                        3                    0.01026                                                *FGF8*, *FOXA2*, *TCF21*
                  GO:0060337     Type I interferon-mediated signaling pathway                              3                    0.04164                                                *OAS2*, *IFI27*, *IFNA13*
                    GO:0045945   Positive regulation of transcription from RNA polymerase III promoter     2                    0.00212                                                *ERBB2*, *FOXA2*
                  GO:0006853     Carnitine shuttle                                                         2                    0.00358                                                *CPT1A*, *PRKAB2*
                  GO:0050860     Negative regulation of T cell receptor signaling pathway                  2                    0.00643                                                *PTPN22*, *ELF1*
                  GO:0071542     Dopaminergic neuron differentiation                                       2                    0.00755                                                *FGF8*, *FOXA2*
  Downregulated   GO:0045444     Fat cell differentiation                                                  11                   0.00074                                                *CTBP1*, *LRP6*, *RETN*, *WNT5B*, *TGFB1I1*, *ALDH6A1*, *SLC2A4*, *AKT1*, *INHBB*, *CREB5*, *CREBL2*
                  GO:0009411     Response to UV                                                            9                    0.00118                                                *TGFB1I1*, *ALDH6A1*, *SLC2A4*
                  GO:0009880     Embryonic pattern specification                                           5                    0.01686                                                *AKT1*, *INHBB*, *CREB5*, *CREBL2*
                  GO:0002089     Lens morphogenesis in camera-type eye                                     4                    0.00275                                                *MSH6*, *ZRANB3*, *XPA*, *AKT1*
                  GO:0043044     ATP-dependent chromatin remodeling                                        4                    0.00985                                                *N4BP1*, *PIK3R1*, *SPRTN*, *REV1*, *HYAL1*
                  GO:0035690     Cellular response to drug F                                               4                    0.02375                                                *LRP6*, *TDGF1*, *TFAP2A*, *COBL*, *PCSK6*
                  GO:0071364     Cellular response to epidermal growth factor stimulus                     3                    0.00459                                                *PVRL3*, *TFAP2A*, *PROX1*, *CITED2*
                  GO:0010765     Positive regulation of sodium ion transport                               3                    0.01115                                                *RBBP7*, *RSF1*, *NASP*, *SMARCAD1*
                  GO:0021516     Dorsal spinal cord development                                            3                    0.01475                                                *CAD*, *PPM1F*, *TXN*, *KCNH2*
                  GO:0086091     Regulation of heart rate by cardiac conduction                            3                    0.01475                                                *CAD*, *AKT1*, *TDGF1*

Fisher\'s exact test. GO, gene ontology; DEG, differentially-expressed genes; NF, nuclear factor; UV, ultraviolet; ATP, adenosine triphosphate.

###### 

Enriched KEGG signaling pathways for DEGs.

  Type of DEG     KEGG no.   KEGG signaling pathway                      No. of DEGs enriched   P-value^[a](#tfn3-ol-0-0-5497){ref-type="table-fn"}^   Genes
  --------------- ---------- ------------------------------------------- ---------------------- ------------------------------------------------------ ---------------------------------------------------------
  Upregulated     4020       Calcium signaling pathway                   5                      0.01949                                                *CHP2*, *AVPR1B*, *CAMK2D*, *ERBB2*, *CALM2*
                  4720       Long-term potentiation                      4                      0.00326                                                *CHP2*, *CAMK2D*, *EP300*, *CALM2*
                  3040       Spliceosome                                 4                      0.02543                                                *SNRPD1*, *SRSF4*, *TXNL4A*, *CCDC12*
                  4650       Natural killer cell mediated cytotoxicity   4                      0.03167                                                *RAET1E*, *CHP2*, *TNFRSF10B*, *IFNA13*
                  4012       ErbB signaling pathway                      3                      0.04129                                                *CAMK2D*, *ERBB2*, *GAB1*
                  4210       Apoptosis                                   3                      0.04129                                                *CHP2*, *APAF1*, *TNFRSF10B*
                  511        Other glycan degradation                    2                      0.00962                                                *GLB1*, *GBA*
                  4744       Phototransduction                           2                      0.02683                                                *GUCA1B*, *CALM2*
                  600        Sphingolipid metabolism                     2                      0.04847                                                *GLB1*, *GBA*
  Downregulated   4920       Adipocytokine signaling pathway             6                      0.00374                                                *RXRB*, *SLC2A4*, *LEPR*, *AKT1*, *CAMKK2*, *MAPK10*
                  4662       B-cell receptor signaling pathway           6                      0.00607                                                *RASGRP3*, *PIK3AP1*, *AKT1*, *BTK*, *PIK3R1*, *NFATC3*
                  5223       Non-small cell lung cancer                  4                      0.03098                                                *RXRB*, *AKT1*, *PIK3R1*, *RASSF1*
                  4012       ErbB signaling pathway                      5                      0.04306                                                *AKT1*, *EREG*, *PIK3R1*, *ELK1*, *MAPK10*
                  5210       Colorectal cancer                           4                      0.04781                                                *MSH6*, *AKT1*, *PIK3R1*, *MAPK10*

Fisher\'s exact test. KEGG, Kyoto Encyclopedia of Genes and Genomes; DEG, differentially-expressed genes.

###### 

TFs and TAGs among the DEGs.

                  TFs   TAGs                                                                                                                                                      
  --------------- ----- ---------------------------------------------------------------------------------------------------------------------------------------------------- ---- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Upregulated     10    *EP300, RARG, HOXB13, RORA, FOXA2, TCF21, ELF, SIX5, CCNT2, SUPT4H1*                                                                                 13   *ERBB2, FGF8, MLLT11, MT1G, APAF1, HOXB13, TNFRSF10B, PDLIM4, FOXA2, DAPK3, CLU, MTUS1, FHL2*
  Downregulated   21    *CTBP1, GTF2A1, RORB, RXRB, HOXB4, TGFB1I1, LMX1B, NR2F6, KCNIP3, CDX4, SKIL, GABPB2, MEIS3, NKX6-1, PAX3, ELK1, NFATC3, SIM1, FOXD1, PROX1, RFX5*   28   *MLF1, FGF20, CTTN, SKIL, AKT1, EWSR1, ELK1, DCUN1D1, CTBP1, PTPN2, RBBP7, FBXO32, TGFBI, SIRT3, NEO1, RARRES1, PER1, SPINK7, CBFA2T3, ENC1, CREBL2, PROX1, RASSF1, MSH6, PAX3, DDX6, TFAP2A, DHX16*

TF, transcription factor; TAG, tumor-associated gene; DEG, differentially-expressed genes.

###### 

DEGs in the top 10% of nodes with a high connectivity degree in the PPI.

  DEG         STRING degree of connectivity
  ----------- -------------------------------
  *AKT1*      37
  *EP300*     25
  *CALM2*     23
  *PIK3R1*    18
  *ATN1*      11
  *PRKCZ*     11
  *SNRPD1*    10
  *EEF2*      10
  *MSH6*      10
  *ERBB2*       9
  *RBBP7*       9
  *GNB2L1*      9
  *TLR9*        9
  *RRM1*        9
  *BTK*         8
  *SLC2A4*      8
  *TFIP11*      8
  *GRP*         8
  *DYNLT3*      8
  *ADRA1D*      7
  *NASP*        7
  *ARHGEF7*     7
  *TXNL4A*      7
  *TXN*         7
  *GRB10*       7

DEG, differentially-expressed gene; STRING, Search Tool for the Retrieval of Interacting Genes.

###### 

Top 10 enriched GO functions for DEGs in the functional module.

  GO no.       GO function                                                                 No. of DEGs enriched   P-value^[a](#tfn6-ol-0-0-5497){ref-type="table-fn"}^   Genes
  ------------ --------------------------------------------------------------------------- ---------------------- ------------------------------------------------------ -----------------------------------
  GO:0046777   Protein autophosphorylation                                                 5                          0.0000425                                          *CAD, DAPK3, CAMKK2, ERBB2, AKT1*
  GO:0007565   Female pregnancy                                                            4                      0.00034                                                *UPRT, CAD, CITED2, AKT1*
  GO:0043547   Positive regulation of GTPase activity                                      4                      0.00037                                                *RASGRF1, ERBB2, ARHGEF7, GNB2L1*
  GO:0019221   Cytokine-mediated signaling pathway                                         4                      0.00586                                                *IFNAR2, EIF4A1, EREG, PTPN2*
  GO:0042059   Negative regulation of epidermal growth factor receptor signaling pathway   3                          0.0000918                                          *TFAP2A, PTPN2, ARHGEF7*
  GO:0042593   Glucose homeostasis                                                         3                      0.00340                                                *PTPN2, TXN, AKT1*
  GO:0051151   Negative regulation of smooth muscle cell differentiation                   2                      0.00016                                                *RCAN1, EREG*
  GO:0006222   UMP biosynthetic process                                                    2                      0.00025                                                *UPRT, CAD*
  GO:0010765   Positive regulation of sodium ion transport                                 2                      0.00075                                                *AKT1, SCN3B*
  GO:0021602   Cranial nerve morphogenesis                                                 2                      0.00092                                                *TFAP2A, CITED2*

Fisher\'s exact test. GO, gene ontology; DEG, differentially-expressed gene; GTPase, guanosine triphosphatase; UMP, uracil monophosphate.

###### 

Enriched KEGG signaling pathways for DEGs in the functional module.

  KEGG no.   KEGG signaling pathway            No. of DEGs enriched   P-value^[a](#tfn7-ol-0-0-5497){ref-type="table-fn"}^   Genes
  ---------- --------------------------------- ---------------------- ------------------------------------------------------ ------------------------
  4012       ErbB signaling pathway            3                      0.00126                                                *EREG, ERBB2, AKT1*
  4510       Focal adhesion                    3                      0.01310                                                *RASGRF1, ERBB2, AKT1*
  5200       Pathways in cancer                3                      0.04696                                                *DAPK3, ERBB2, AKT1*
  5219       Bladder cancer                    2                      0.00495                                                *DAPK3, ERBB2*
  5213       Endometrial cancer                2                      0.00751                                                *ERBB2, AKT1*
  5223       Non-small cell lung cancer        2                      0.00808                                                *ERBB2, AKT1*
  5214       Glioma                            2                      0.01155                                                *AKT1, CALM2*
  4920       Adipocytokine signaling pathway   2                      0.01260                                                *CAMKK2, AKT1*
  5212       Pancreatic cancer                 2                      0.01332                                                *ERBB2, AKT1*
  5215       Prostate cancer                   2                      0.02100                                                *ERBB2, AKT1*

Fisher\'s exact test. KEGG, Kyoto Encyclopedia of Genes and Genomes; DEG, differentially-expressed genes.
